Evidence map›Paper›PMID 40353301›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2025

Procalcitonin as a Predictive Marker of Incident Liver Disease.

Amanda Finnberg-Kim, Mats Pihlsgård, Kristina Önnerhag, Olle Melander, Sofia Enhörning

Abstract read
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amanda Finnberg-KimDepartment of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.ORCID 0009-0006-0023-719X
Mats PihlsgårdPerinatal and Cardiovascular Epidemiology, Lund University Diabetes Centre, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.
Kristina ÖnnerhagDepartment of Gastroenterology and Hepatology, Skåne University Hospital, Malmö, Sweden.
Olle MelanderDepartment of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.
Sofia EnhörningPerinatal and Cardiovascular Epidemiology, Lund University Diabetes Centre, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.

Funding

Åke Wiberg StiftelseCrafoordska StiftelsenDirektör Albert Påhlssons StiftelseHjärt-LungfondenMaggie Stephen FoundationSkånes universitetssjukhusSvenska LäkaresällskapetSvenska Sällskapet för Medicinsk ForskningVetenskapsrådet
6 · The paper itself

Abstract

BACKGROUND AND

aimsPrevious studies have shown that procalcitonin (PCT) concentration is elevated in patients with liver disease without evidence of bacterial infection. We aimed to investigate the association between elevated PCT and the future risk of liver disease.

methodPCT was measured in 3897 individuals without known liver disease in the Malmö Diet and Cancer Cardiovascular Cohort (MDC-CC) and in 3854 individuals in the Malmö Preventive Project cohort (MPP). Cox proportional hazards regression models were used to analyse the risk of register-verified incident liver disease by PCT levels. We performed our analyses in a pooled sample of both the MPP and MDC-CC cohorts, as well as separate analyses for each cohort.

results70 subjects in MDC-CC and 49 subjects in MPP were diagnosed with non-viral liver disease during a median follow-up of 27.1 and 14.8 years, respectively. In multivariate adjusted models in the pooled sample, individuals with high PCT (> 0.05 ng/mL) had a significantly increased risk of developing liver disease compared to subjects with PCT concentrations below the cutoff (hazard ratio (HR) 3.4, 95% confidence interval (CI) 2.07-5.63, p < 0.001). The HR per standard deviation increase of log-transformed PCT was 1.56 (95% CI 1.32-1.85, p < 0.001) in multivariate adjusted models. Separate cohort-specific sensitivity analyses, including additional adjustment for C-reactive protein, showed similar effect estimates as the pooled analyses.

conclusionsElevated concentration of PCT independently predicts non-viral liver disease. These findings could have implications for risk assessment but also highlight the possibility of PCT as a direct cause of hepatocyte damage.

Indexed as

Liver DiseasesProcalcitoninAgedBiomarkersFemaleHumansIncidenceMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsProportional Hazards ModelsRisk FactorsSwedenBiomarkersProcalcitoninC‐reactive proteinliver cirrhosisliver diseaseprocalcitoninrisk assessment

Identifiers

PMID40353301
PMCPMC12067363

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.